Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BON Bon Natural Life	$0.06 -3.8%	$0.27	$0.05 ▼ $3.37	$231K	-0.47	9.01 million shs	11.05 million shs
EVFM Evofem Biosciences	$0.01 +2.4%	$0.01	$0.01 ▼ $0.02	$975K	-1	496,319 shs	12,495 shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	109 shs
SXTC China SXT Pharmaceuticals	$2.01 +5.8%	$2.64	$0.95 ▼ $11.92	$1.37M	1.24	1.06 million shs	571,537 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BON Bon Natural Life	+1.24%	-13.33%	-14.63%	-95.67%	-97.85%
EVFM Evofem Biosciences	-2.33%	-4.55%	+2.44%	-9.68%	-38.01%
NMTR 9 Meters Biopharma	0.00%	0.00%	0.00%	0.00%	+6,463.64%
SXTC China SXT Pharmaceuticals	-8.05%	-19.44%	-27.78%	-40.60%	-79.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	0.2385 of 5 stars	0.0	0.0	0.0	4.8	0.0	0.0	0.0
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.4762 of 5 stars	0.0	4.0	0.0	0.0	1.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BON Bon Natural Life	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BON Bon Natural Life	$23.84M	0.01	$0.07 per share	0.78	$37.78 per share	0.00
EVFM Evofem Biosciences	$11.39M	0.09	N/A	N/A	($2.64) per share	0.00
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
SXTC China SXT Pharmaceuticals	$1.82M	0.80	N/A	N/A	$30.46 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BON Bon Natural Life	$400K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	$52.98M	-$0.21	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BON Bon Natural Life	0.02	2.42	2.32
EVFM Evofem Biosciences	N/A	0.11	0.09
NMTR 9 Meters Biopharma	N/A	0.59	0.59
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BON Bon Natural Life	0.57%
EVFM Evofem Biosciences	0.22%
NMTR 9 Meters Biopharma	22.34%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
BON Bon Natural Life	26.48%
EVFM Evofem Biosciences	0.21%
NMTR 9 Meters Biopharma	2.40%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BON Bon Natural Life	100	4.17 million	863,000	Not Optionable
EVFM Evofem Biosciences	120	113.36 million	113.12 million	Not Optionable
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
SXTC China SXT Pharmaceuticals	90	723,000	3.90 million	Not Optionable

BON, EVFM, NMTR, and SXTC Headlines

Recent News About These Companies

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.com

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.com

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 2, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.com

JAGX, BSGM and SXTC among mid-day movers

April 16, 2024 | msn.com

China SXT Pharmaceuticals Inc.

February 23, 2024 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
3 Bond ETFs for the Diversified Investor
By Chris Markoch | April 13, 2025
View 3 Bond ETFs for the Diversified Investor
Buffett Loves Occidental Petroleum—Should You? 4 Pros, 3 Cons
By Jea Yu | April 15, 2025
View Buffett Loves Occidental Petroleum—Should You? 4 Pros, 3 Cons
Is It Time to Load Up on Bond ETFs?
By Nathan Reiff | May 2, 2025
View Is It Time to Load Up on Bond ETFs?

BON, EVFM, NMTR, and SXTC Company Descriptions

Bon Natural Life NYSE:BON

$0.06 0.00 (-3.83%)

Closing price 03:58 PM Eastern

Extended Trading

$0.05 0.00 (-2.71%)

As of 07:59 PM Eastern

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.

Evofem Biosciences NASDAQ:EVFM

$0.0086 +0.00 (+2.38%)

As of 02:54 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.01 +0.11 (+5.79%)

Closing price 04:00 PM Eastern

Extended Trading

$1.99 -0.02 (-1.00%)

As of 07:50 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time